{"id":64318,"date":"2026-04-30T14:47:20","date_gmt":"2026-04-30T06:47:20","guid":{"rendered":"https:\/\/flcube.com\/?p=64318"},"modified":"2026-04-30T14:47:21","modified_gmt":"2026-04-30T06:47:21","slug":"3sbio-reports-94-revenue-surge-to-2-58b-in-2025-driven-by-6b-pfizer-pd-1-vegf-bispecific-antibody-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64318","title":{"rendered":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal"},"content":{"rendered":"\n<p><strong>3SBio Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1530:HKG\">HKG: 1530<\/a>) reported <strong>2025 financial results<\/strong> with <strong>revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion)<\/strong> and <strong>net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion)<\/strong>. The extraordinary growth was primarily fueled by <strong>licensing income from its landmark alliance with Pfizer<\/strong> for <strong>707<\/strong>, a breakthrough <strong>PD-1\/VEGF bispecific antibody (BsAb)<\/strong>, in a deal valued at <strong>over USD 6 billion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights-fy-2025\">Financial Highlights \u2013 FY 2025<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenues<\/strong><\/td><td>RMB 17.7B (USD 2.58B)<\/td><td>+94.3%<\/td><\/tr><tr><td><strong>Net Profits<\/strong><\/td><td>RMB 8.48B (USD 1.23B)<\/td><td>+305.8%<\/td><\/tr><tr><td><strong>Biological Product Sales<\/strong><\/td><td>RMB 8.006B (USD 1.17B)<\/td><td>+10.3%<\/td><\/tr><tr><td><strong>CDMO Business Revenue<\/strong><\/td><td>RMB 264M (USD 38.6M)<\/td><td>+46.3%<\/td><\/tr><tr><td><strong>Pfizer Deal Value<\/strong><\/td><td>Over USD 6B (USD 1.4B upfront + USD 100M equity)<\/td><td>N\/A<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-pfizer-alliance\">Strategic Partnership \u2013 Pfizer Alliance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Asset<\/strong><\/td><td>707 \u2013 breakthrough PD-1\/VEGF bispecific antibody (BsAb)<\/td><\/tr><tr><td><strong>Partnership Value<\/strong><\/td><td>Over USD 6 billion total consideration<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 1.4 billion<\/td><\/tr><tr><td><strong>Equity Component<\/strong><\/td><td>USD 100 million collaboration investment<\/td><\/tr><tr><td><strong>Strategic Impact<\/strong><\/td><td>Transforms 3SBio from domestic biologics player to global innovation partner<\/td><\/tr><tr><td><strong>Revenue Recognition<\/strong><\/td><td>Significant portion recognized in 2025 financials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-amp-regulatory-milestones\">Product Portfolio &amp; Regulatory Milestones<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-new-drug-approvals-2025\">New Drug Approvals (2025)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Yisaita (amdokitug)<\/strong>: Newly approved therapeutic<\/li>\n\n\n\n<li><strong>Xinbiao (loncipoetin alfa)<\/strong>: Erythropoiesis-stimulating agent expansion<\/li>\n\n\n\n<li><strong>Eltrombopag olamine<\/strong>: Thrombopoietin receptor agonist for additional indications<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-product-expansion\">Core Product Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Recombinant Human Thrombopoietin<\/strong>: Approved for new indication \u2013 <strong>treatment of thrombocytopenia associated with chronic liver disease (CLDT)<\/strong> in patients planning surgical or diagnostic procedures<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: Expands addressable patient population and reinforces leadership in hematology therapeutics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-segment-performance\">Business Segment Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>2025 Revenue<\/th><th>Growth Driver<\/th><\/tr><\/thead><tbody><tr><td><strong>Biological Products<\/strong><\/td><td>RMB 8.006B<\/td><td>Core product portfolio expansion and new indications<\/td><\/tr><tr><td><strong>CDMO Services<\/strong><\/td><td>RMB 264M<\/td><td>46.3% growth reflecting expanding contract manufacturing capabilities<\/td><\/tr><tr><td><strong>Licensing &amp; Partnerships<\/strong><\/td><td>Majority of revenue growth<\/td><td>Pfizer deal representing transformational partnership value<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-development-mandi-inc-spin-off\">Corporate Development \u2013 Mandi Inc. Spin-off<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Subsidiary<\/strong>: <strong>Mandi Inc.<\/strong> focusing on <strong>hair loss, dermatology, and body weight management<\/strong><\/li>\n\n\n\n<li><strong>Strategic Action<\/strong>: Proposed <strong>separate listing on Hong Kong Stock Exchange<\/strong><\/li>\n\n\n\n<li><strong>Rationale<\/strong>: Unlock shareholder value by separating high-growth consumer health assets from core biopharmaceutical business<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Dermatology and weight management represent rapidly growing consumer health segments in China<\/li>\n\n\n\n<li><strong>Execution Timeline<\/strong>: Subject to regulatory approvals and market conditions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-outlook\">Strategic Implications &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Recognition<\/strong>: Pfizer partnership validates 3SBio&#8217;s bispecific antibody platform and establishes international credibility<\/li>\n\n\n\n<li><strong>Financial Transformation<\/strong>: One-time licensing income creates war chest for internal R&amp;D investment and strategic acquisitions<\/li>\n\n\n\n<li><strong>Diversification Strategy<\/strong>: Spin-off of Mandi Inc. enables focused execution in both biopharmaceutical and consumer health markets<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: PD-1\/VEGF bispecific represents next-generation immuno-oncology approach with potential advantages over monospecific antibodies<\/li>\n\n\n\n<li><strong>Sustainable Growth<\/strong>: Strong underlying biological product sales (+10.3%) demonstrate robust core business fundamentals beyond partnership income<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, regulatory timelines, partnership execution, and corporate development activities. Actual results may differ due to risks including market volatility, regulatory decisions, competitive dynamics, and capital market conditions affecting the proposed Mandi Inc. spin-off.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042908453345522.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026042908453345522.\"><\/object><a id=\"wp-block-file--media-a6aa8401-12dd-4bfe-81fa-a601c9517f0b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042908453345522.pdf\">2026042908453345522<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026042908453345522.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a6aa8401-12dd-4bfe-81fa-a601c9517f0b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[116,27,1061,309],"class_list":["post-64318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-3sbio","tag-finanical-reports","tag-hkg-1530","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64318\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal\" \/>\n<meta property=\"og:description\" content=\"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64318\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:47:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:47:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\\\/VEGF Bispecific Antibody Deal\",\"datePublished\":\"2026-04-30T06:47:20+00:00\",\"dateModified\":\"2026-04-30T06:47:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3003.webp\",\"keywords\":[\"3SBio\",\"Finanical Reports\",\"HKG: 1530\",\"Pfizer\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64318#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64318\",\"name\":\"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\\\/VEGF Bispecific Antibody Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3003.webp\",\"datePublished\":\"2026-04-30T06:47:20+00:00\",\"dateModified\":\"2026-04-30T06:47:21+00:00\",\"description\":\"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\\\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64318\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3003.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3003.webp\",\"width\":1080,\"height\":608,\"caption\":\"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\\\/VEGF Bispecific Antibody Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64318#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\\\/VEGF Bispecific Antibody Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal - Insight, China&#039;s Pharmaceutical Industry","description":"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64318","og_locale":"en_US","og_type":"article","og_title":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal","og_description":"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.","og_url":"https:\/\/flcube.com\/?p=64318","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:47:20+00:00","article_modified_time":"2026-04-30T06:47:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64318#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64318"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal","datePublished":"2026-04-30T06:47:20+00:00","dateModified":"2026-04-30T06:47:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64318"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64318#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","keywords":["3SBio","Finanical Reports","HKG: 1530","Pfizer"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64318#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64318","url":"https:\/\/flcube.com\/?p=64318","name":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64318#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64318#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","datePublished":"2026-04-30T06:47:20+00:00","dateModified":"2026-04-30T06:47:21+00:00","description":"3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to RMB 17.7 billion (USD 2.58 billion) and net profits skyrocketing 305.8% YOY to RMB 8.48 billion (USD 1.23 billion). The extraordinary growth was primarily fueled by licensing income from its landmark alliance with Pfizer for 707, a breakthrough PD-1\/VEGF bispecific antibody (BsAb), in a deal valued at over USD 6 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64318#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64318"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64318#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","width":1080,"height":608,"caption":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64318#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1\/VEGF Bispecific Antibody Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3003.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64318"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64318\/revisions"}],"predecessor-version":[{"id":64321,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64318\/revisions\/64321"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64320"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}